AGL · agilon health, inc.

The thesis

agilon health's margin recovery is reported but not yet repeated. The third-quarter report on 4 November 2026 settles it: medical margin of at least $105 million and the $465 million full-year floor intact would confirm the August repair. The shares closed at $90.65 on 27 October 2026, 30.2% below the 52-week high of $129.84.

Medical margin is revenue less medical costs. It is the line that matters because the company books revenue before those costs arrive. The benchmarks come from the 5 August 2026 results release: Q3 medical margin of $105–$115 million, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) between negative $5 million and positive $5 million, and the $465 million full-year floor. The company's 5 October 2026 release set results for after the market close on 4 November 2026, with a call at 4:30 p.m. ET.

The narrative is maturing: the story has been well known since Bernstein's 15 September 2026 upgrade, and the only company disclosure since then is the date-setting release. The shares are down 6.3% over three months, and the 14-day relative strength index (RSI) read 61.1 on 27 October 2026, down from 73.0 on 14 October 2026. That cooling leaves the report as the next source of new evidence.

Conviction stays low. The case is real, but one report eight days away carries the outcome, and a stock with a reported beta of 3.02 can move sharply on a small miss against guidance.

Bullish and bearish views on agilon health, inc.

The bull case on agilon health, inc. (AGL), in brief: Margin repair is reported, not projected. The bear case: Guidance already steps down.

Bull case

• Margin repair is reported, not projected. Q2 2026 medical margin was $197 million against negative $53 million in Q2 2025, per the company's 5 August 2026 results release. The $465 million full-year floor came in the same release.
• Analysts sit well above the price. Bernstein upgraded agilon to Outperform on 15 September 2026 and raised its target to $125 from $86. MarketBeat's 25 September 2026 summary showed a consensus target of $102.25 against the $90.65 close on 27 October 2026.
• The 200-day average sits far below the price. MarketBeat reported a 200-day moving average of $74.10 on 25 September 2026. The $90.65 close on 27 October 2026 is above it.

• Expansion has a named channel. The 10 September 2026 release adds Family Practice Center to a Senior Health Connect accountable care organization in the Medicare Shared Savings Program. The company gave no figures with it.

Bear case

• Guidance already steps down. The company guided Q3 medical margin to $105–$115 million on 5 August 2026, against $197 million in Q2. Q2 included prior-period risk-adjustment true-ups, so it is not a run-rate.
• Membership is shrinking. Q2 platform membership was 549,000, down about 10% year over year, per the 5 August 2026 release.
• The ACO REACH model ends this year. About 112,000 members sat in the Accountable Care Organization Realizing Equity, Access, and Community Health (ACO REACH) model at Q2 2026, and its final performance year is 2026. The company has not quantified the 2027 member base.
• Skeptics remain. JPMorgan kept an Underweight rating and raised its target to $85 on 24 August 2026, per Benzinga. MarketBeat showed a consensus rating of Hold on 25 September 2026.
• The shares are volatile. MarketBeat reported a beta of 3.02 on 25 September 2026, and the company had 16.8 million common shares outstanding at 30 June 2026.

Price setup

The last completed daily close was $90.65 on 27 October 2026. The 52-week high is $129.84. MarketBeat's 50-day moving average was $94.72 and its 200-day moving average was $74.10 on 25 September 2026, so the latest close sits between the two.

Crowding evidence is mixed. The report is eight days away, and the shares have a high beta and a small share count. RSI has cooled from 73.0 on 14 October 2026 to 61.1, so the sharp mid-October rebound has eased. No Form 4 insider transactions or new share issuance appear in company filings since the prior note.

Catalysts, next 30 days

• 31 December 2026 (outside the 30-day window): The ACO REACH model's final performance year ends. The 2027 member base depends on it, and the Q3 call may give the first outlook.

Elapsed catalysts

• 4 November 2026, after the market close: Q3 2026 results and a 4:30 p.m. ET call. The report tests Q3 medical margin against the $105–$115 million guide and the $465 million full-year floor. (passed 2d ago)

What would change the view

The case breaks if Q3 medical margin comes in below the $105 million low end of guidance, or if the company cuts the $465 million full-year floor. Either would show the Q2 repair was largely true-ups. A 2027 outlook that shows further member losses, with no quantified gain from the Family Practice Center expansion, would weaken it as well.

On price, a weekly close below $74, near the 200-day moving average MarketBeat reported on 25 September 2026, would mark a loss of the longer-term trend. A report at or above the guide, with the floor held or raised, would move the read toward a medium-conviction view.

What it trades with

agilon's results depend on Medicare Advantage medical-cost trends and on payer risk-adjustment payments. Moves in large Medicare Advantage insurers' cost commentary can carry over to the shares. Its beta of 3.02 per MarketBeat means broad market swings are magnified.